

Paper No. ____
Filed: December 14, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LUPIN LTD. and LUPIN PHARMACEUTICALS INC.
Petitioner

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
BAUSCH & LOMB PHARMA HOLDINGS CORP.,
Patent Owner

Case IPR2015-01100
U.S. Patent 8,927,606

PATENT OWNER'S EXHIBIT LIST

Further to 37 C.F.R. § 42.63(e), Patent Owner Senju Pharmaceutical Co.,
Ltd., hereby submits a current listing of Senju Exhibits to counsel for Petitioner
Lupin Ltd. and Lupin Pharmaceuticals Inc.

| Exhibits | Description |
|-----------------|---|
| Exhibit 2001 | U.S. Patent No. 8,129,431 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.” |
| Exhibit 2002 | Lupin’s Paragraph IV Notice Letter dated December 19, 2013. |
| Exhibit 2003 | Lupin’s Paragraph IV Notice Letter dated May 13, 2014. |
| Exhibit 2004 | Lupin’s Paragraph IV Notice Letter dated July 3, 2014. |
| Exhibit 2005 | Lupin’s Paragraph IV Notice Letter dated December 17, 2014. |
| Exhibit 2006 | Lupin’s Paragraph IV Notice Letter dated February 19, 2015. |
| Exhibit 2007 | Complaint, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-00667 (D.N.J. Jan. 31, 2014), ECF No. 1. |
| Exhibit 2008 | Complaint, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-04149 (D.N.J. June 26, 2014), ECF No. 1. |
| Exhibit 2009 | Complaint, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-05144 (D.N.J. Aug. 15, 2014), ECF No. 1. |
| Exhibit 2010 | Complaint, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 15-cv-00335 (D.N.J. Jan. 16, 2015), ECF No. 1. |
| Exhibit 2011 | Consolidated scheduling order, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No. 14-cv-06893 (D.N.J. April 16, 2015), ECF No. 30. |
| Exhibit 2012 | Amended scheduling order, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-00667 (D.N.J. Feb. 27, 2015), ECF No. 63. |
| Exhibit 2013 | U.S. Patent No. 5,630,793 to Rowe, “Aqueous Ophthalmic Sprays.” |
| Exhibit 2014 | Press Release by Bausch + Lomb, dated April 8, 2013, entitled “Bausch + Lomb Receives FDA Approval for Prolensa™ (bromfenac ophthalmic solution) 0.07%.” |
| Exhibit 2015 | InnoPharma’s Paragraph IV Notice Letter dated September 19, 2014. |
| Exhibit 2016 | InnoPharma’s Paragraph IV Notice Letter dated October 30, 2014. |

| | |
|--------------|--|
| Exhibit 2017 | InnoPharma's Paragraph IV Notice Letter dated March 27, 2015. |
| Exhibit 2018 | InnoPharma's Paragraph IV Notice Letter dated June 12, 2015. |
| Exhibit 2019 | Metrics' Paragraph IV Notice Letter dated June 26, 2014. |
| Exhibit 2020 | Paddock's Paragraph IV Notice Letter dated December 15, 2014. |
| Exhibit 2021 | Paddock's Paragraph IV Notice Letter dated January 20, 2015. |
| Exhibit 2022 | Apotex's Paragraph IV Notice Letter dated December 10, 2014. |
| Exhibit 2023 | Watson's Paragraph IV Notice Letter dated June 1, 2015. |
| Exhibit 2024 | Masson et al., <i>Stabilisation of ionic drugs through complexation with non-ionic and ionic cyclodextrins</i> , 164 INT'L J. PHARMACEUTICS 45 (1998). |
| Exhibit 2025 | Loftsson et al., <i>Pharmaceutical Applications of Cyclodextrins</i> , 85 J. PHARMACEUTICAL SCIENCES 1017 (1996). |
| Exhibit 2026 | HSBC Global Research Lupin Company Report, Feb. 3, 2014, http://www.lupin.com/pdf/14/20140203%20-%20Lupin%203QFY14%20-%20HSBC.pdf |
| Exhibit 2027 | Consent judgment, <i>Senju Pharm. Co., Ltd. et al. v. Apotex Inc. et al.</i> , No. 15-cv-00336 (D.N.J. May 18, 2015), ECF No. 26. |
| Exhibit 2028 | Consent judgment, <i>Senju Pharm. Co., Ltd. et al. v. Paddock Labs., LLC et al.</i> , No. 15-cv-00337 (D.N.J. June 5, 2015), ECF No. 33. |
| Exhibit 2029 | Consent judgment, <i>Senju Pharm. Co., Ltd. et al. v. Metrics, Inc. et al.</i> , No. 14-cv-03962 (D.N.J. July 1, 2015), ECF No. 108. |
| Exhibit 2030 | U.S. Patent No. 5,856,345 to Doi et al., "Method for Stabilizing Pranoprofen and Stable Liquid Preparation of Pranoprofen." |
| Exhibit 2031 | Drugs@FDA, Listing of FDA-approved bromfenac ophthalmic solution 0.09% products, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=BROMFENAC%20SO DIUM . |
| Exhibit 2032 | Sheryl Gay Stolberg, <i>New Painkiller is Withdrawn After 4 Deaths</i> , N.Y. TIMES, Jun. 23, 1998. |
| Exhibit 2033 | Baklayan et al., <i>The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model</i> , CLINICAL OPHTHALMOLOGY 1717 (2014). |
| Exhibit 2034 | Schott, <i>Effect of inorganic additives on solutions of nonionic surfactants – XVI. Limiting cloud points of highly polyoxyethylated surfactants</i> , 186 COLLOIDS AND SURFACES A: PHYSICOCHEMICAL |

| | |
|--------------|---|
| | AND ENGINEERING ASPECTS 129 (2001). |
| Exhibit 2035 | European Patent No. 0274870 to Story, M., et al., "Micelles containing a non-steroidal antiinflammatory compound" (filed December 12, 1987; issued July 7, 1988). |
| Exhibit 2036 | Reddy, Indra K., <i>Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach</i> , 42-43, 390 (1996). |
| Exhibit 2037 | Declaration of Uday B. Kompella in Support of Plaintiffs' Proposed Claim Constructions, <i>Insite Vision Inc. et al. v. Sandoz Inc. et al.</i> , No. 11-cv-03080, 2012 WL8667473 (D.N.J. April 12, 2012). |
| Exhibit 2038 | Transcript of Teleconference with the Board, dated December 11, 2015 |

Respectfully submitted,

Dated: December 14, 2015

By: /Bryan C. Diner/
Bryan C. Diner, Lead Counsel
Reg. No. 32,409
Finnegan, Henderson, Farabow, Garrett
& Dunner, L.L.P.
901 New York Ave. NW
Washington, DC 20001-4413

Counsel for Patent Owner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **Patent Owner's Updated Exhibit List and Exhibit 2038** were served on December 14, 2015, via email directed to counsel of record for the Petitioner at the following:

Deborah Yellin
DYellin@crowell.com

Jonathan Lindsay
JLindsay@crowell.com

Date: December 14, 2015

/Ashley F. Cheung/
Ashley F. Cheung
Case Manager

Finnegan, Henderson, Farabow, Garrett &
Dunner, LLP